Hi! I’m Doug, the founder of Pace Pharmaceuticals. We’re developing drugs for neurological diseases.
Drug discovery is notoriously slow and expensive — but it doesn’t have to be. We’ve streamlined the discovery process to be 100× cheaper than usual, allowing us to generate clinical-trial-ready drugs at unprecedented efficiency.
We currently have two compound series that have completed the discovery phase for Alzheimer’s disease and schizophrenia, respectively.
The world’s first selective small-molecule GalR1 antagonist for Alzheimer’s disease.
Selective M4 agonist for schizophrenia.
These compounds are now undergoing IND-enabling studies and will enter clinical testing within the next year.
Our short-term target (1–2 years from now) is 10 clinical-stage drugs. Our long-term target (~10 years from now) is 1,000 clinical-stage drugs.
Pace Pharmaceuticals will pave the way for a new golden age of drug discovery.